Drug intelligence / Profile preview

AYK203

Development stage: Preclinical
Lead developer: Ayk Biotechnology
Modality: Vaccines & Immunotherapeutics

Overview

**AYK203** is an investigational therapeutic tumor vaccine developed by Shanghai Ayk Biotechnology. The company describes it as a novel tumor vaccine that utilizes heterologous T cells to attack tumors. Animal studies reportedly showed antitumor activity, and proof-of-concept work has been completed; the company stated that an IND submission was planned for 2026. The specific vaccine composition, tumor antigen targets, heterologous T-cell strategy, administration route, and formulation have not been publicly disclosed. ([aykbio.com](https://www.aykbio.com/en/h-col-133.html))

Other names: AYK-203AYK203AYK 203

Beyond the preview

Go deeper on AYK203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AYK203.

Explore the full profile